CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.36BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.22xvs all stocks
52-Week Change
62.22%vs all stocks
Market Capitalization
8.36BUSDvs all stocks (USD)
Enterprise Value
6.99BUSDvs all stocks (USD)
Forward P/E
-7.79xvs Biotechnology peers
Price to Book (MRQ)
2.95xvs Biotechnology peers
Enterprise to EBITDA
-6.09xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.61%vs Biotechnology peers
Return on Equity (TTM)
-36.51%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-1.15BUSDvs all stocks (USD)
Net Income (TTM)
-1.06BUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-881.23MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-485.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-923.67MUSDvs all stocks (USD)
Pre-tax Income
-766.63MUSDFY2025 · Dec 31, 2025Net Income
-766.63MUSDFY2025 · Dec 31, 2025EBIT
-923.67MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-898.82MUSDFY2025 · Dec 31, 2025Research & Development
794.31MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
129.37MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
119.72MUSDFY2025 · Dec 31, 2025EPS (Basic)
-5.63USDFY2025 · Dec 31, 2025EPS (Diluted)
-5.63USDFY2025 · Dec 31, 2025Basic Shares Outstanding
136.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
136.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-766.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-641.03MUSDFY2025 · Dec 31, 2025Free Cash Flow
-698.01MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
175.43MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-766.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
24.86MUSDFY2025 · Dec 31, 2025Stock-based Compensation
138.84MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-14.43MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
19.91MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-43.58MUSDFY2025 · Dec 31, 2025Capital Expenditures
-56.97MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.21BUSDFY2025 · Dec 31, 2025Sale of Investments
1.71BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
437.35MUSDFY2025 · Dec 31, 2025Other Financing Charges
-10.99MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-10.99MUSDFY2025 · Dec 31, 2025Shares Outstanding
144.79MSharesUpdated Sep 28, 2026Float Shares
136.44MSharesUpdated Sep 28, 2026Shares Short
16.13MSharesUpdated Sep 28, 2026Short Ratio
14.61daysvs all stocks
Short % of Shares Outstanding
10.90%vs all stocks
% Held by Insiders
0.50%vs all stocks
% Held by Institutions
113.46%vs all stocks
Total Cash (MRQ)
1.49BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.99USDUpdated Sep 28, 2026Total Debt (MRQ)
115.44MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0419xvs Biotechnology peers
Current Ratio (MRQ)
5.72xvs Biotechnology peers
Book Value per Share (MRQ)
19.05USDUpdated Sep 28, 2026Total Assets
3.00BUSDvs all stocks (USD)
Total Current Assets
1.63BUSDFY2025 · Dec 31, 2025Total Liabilities
317.21MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.38BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
111.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
205.75MUSDFY2025 · Dec 31, 2025Cash
85.42MUSDFY2025 · Dec 31, 2025Cash Equivalents
88.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
173.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.39BUSDFY2025 · Dec 31, 2025Accounts Payable
70.90MUSDFY2025 · Dec 31, 2025Short-term Debt
6.12MUSDFY2025 · Dec 31, 2025Long-term Debt
111.36MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
100.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
134.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.15BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
2.69BUSDvs all stocks (USD)
52-Week Low
33.62USDUpdated Sep 28, 202652-Week High
65.00USDUpdated Sep 28, 202652-Week Change
62.22%vs all stocks
Beta
1.22xvs all stocks
50-Day MA
58.48USDUpdated Sep 28, 2026200-Day MA
54.82USDUpdated Sep 28, 2026Avg 10-Day Volume
1.54MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.20MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-7.63USDUpdated Sep 28, 2026Other Income / Expense
37.33MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Altman Z-Score 14.37: safe zoneNotable
Altman Z-Score: 14.37
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,799,263.917
Levered free cash flow is -$485.76M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -485,755,264Global P5: -208,569,634.4
Market cap is $8.36B, above the global median of $1.15BNotable
Market cap (USD): 8,364,344,676Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule